A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors.

Trial Profile

A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2015

At a glance

  • Drugs Pexastimogene devacirepvec (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer
  • Focus Adverse reactions
  • Sponsors Jennerex
  • Most Recent Events

    • 02 Sep 2011 Actual end date changed from Mar 2010 to Jul 2011 as reported by ClinicalTrials.gov.
    • 01 Sep 2011 Results reported in Nature.
    • 06 Apr 2011 Results presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR-2011), according to a Jennerex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top